English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16714/19009 (88%)
Visitors : 5632663      Online Users : 79
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31723


    標題: Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma
    作者: Kuo, Hsing-Tao
    Que, Jenny
    Lin, Li-Ching
    Yang, Ching-Chieh
    Koay, Lok-Beng
    Lin, Chia-Hui
    貢獻者: Chia Nan Univ Pharm & Sci, Dept Radiat Oncol
    Chia Nan Univ Pharm & Sci, Dept Internal Med, Div Hepatol,Chi Mei Med Ctr
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    Chung Hwa Univ Med Technol, Dept Optometry
    Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management
    關鍵字: cyberknife stereotactic body radiation therapy
    hepatocellular carcinoma
    tumor size
    日期: 2017-12
    上傳時間: 2018-11-30 15:54:16 (UTC+8)
    出版者: Lippincott Williams & Wilkins
    摘要: Stereotactic body radiation therapy (SBRT) for inoperable hepatocellular carcinoma (HCC) offers excellent local control rates. This study retrospectively analyzed the influence of different tumor size on treatment outcomes after SBRT. Between December 2008 and February 2014, 141 HCC patients were treated with Cyberknife SBRT. Patients were divided into 3 groups namely small tumors (<= 4cm), intermediate-sized (>4-<10cm), and large (>= 10cm) tumors. Treatment outcomes, prognoses, and safety at each tumor size were compared and analyzed. A total of 52 patients with small tumors, 55 with intermediate tumors, and 34 patients with large tumors were retrospectively analyzed with a median follow-up of 16 months. Objective responses were achieved at 96.15%, 90.90%, and 76.47% for small, intermediate, and large tumors, respectively (P <= .0001) and the 3-year local control rates were 97.85%, 71.99%, and 82.14%, respectively (P=.0035). The 3-year overall survival rates were 50.26%, 45.29%, and 33.38% for small, intermediate, and large tumors, respectively (P=.3757). No significant differences were found in overall-survival, intra-hepatic recurrence free survival, disease-progression free survival, or distant metastasis-free survival. SBRT offers the best effective local control rate and response rate for small HCCs. However, tumor size did not significantly affect the overall survival rate, intra-hepatic recurrence free rate, or disease-progression free rate.
    關聯: Medicine, v.96, n.50, e9249
    Appears in Collections:[老人服務事業管理系] 期刊論文
    [醫務管理系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    00005792-201712150-00110.pdf344KbAdobe PDF0View/Open
    index.html0KbHTML45View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback